Summary
This large-scale genomic study mapped the genetic regulation of 90 cardiovascular proteins in over 30,000 individuals, identifying 451 protein quantitative trait loci and substantiating findings through mouse knockdown experiments and clinical trial evidence. The authors evaluated existing drug targets and identified 11 novel proteins (including EGF, IL-16, PAPPA, SPON1, F3, ADM, CASP-8, CHI3L1, CXCL16, GDF15 and MMP-12) with causal evidence of involvement in human disease that represent new therapeutic opportunities. These findings provide a comprehensive resource for precision medicine approaches to cardiovascular disease.
UK applicability
The findings are directly applicable to UK research and clinical practice, as cardiovascular disease is a leading cause of morbidity and mortality in the UK population. The identified drug targets and regulatory insights could inform future precision medicine strategies and drug development programmes within UK healthcare and pharmaceutical sectors.
Key measures
Protein quantitative trait loci (pQTL); trans-pQTL gene and regulatory designations; Mendelian randomisation estimates of causal protein–disease associations; mouse knockdown experiments; clinical trial data
Outcomes reported
The study mapped and replicated protein quantitative trait loci (pQTL) for 90 cardiovascular proteins across over 30,000 individuals, identifying 451 pQTLs for 85 proteins. It evaluated known drug targets and identified 11 novel proteins with causal evidence of involvement in human disease that had not previously been targeted.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.